New hope for pancreatic cancer: Low-Dose chemo combo followed by targeted maintenance therapy

This study is for people with untreated metastatic pancreatic cancer that has spread to other parts of the body. Participants first receive a low-dose combination of five chemotherapy drugs, then continue with two maintenance medications (olaparib and pembrolizumab) to help keep the cancer under control. The goal is to see if this approach improves how long the cancer stays stable or shrinks, while monitoring side effects. About 38 adults with good performance status are being enrolled.